Modus Operandi for Rehabilitating Aids with Tetrasilver Tetroxide Molecular Crystal Devices

Full text

Research J. Pharm. and Tech. 12(3): March 2019
1418
ISSN 0974-3618 (Print) www.rjptonline.org
0974-360X (Online)
REVIEW ARTICLE
Modus Operandi for Rehabilitating Aids with Tetrasilver Tetroxide
Molecular Crystal Devices
Thiruchelvi. R*1, Aryaman Das
Department of Bio-Engineering, School of Engineering, Vels Institute of Science,
Technology and Advanced Studies, Pallavaram, Chennai– 600 117, Tamil Nadu, India.
*Corresponding Author E-mail: thiruchelvi.se@velsuniv.ac.in
ABSTRACT:
AIDS is a set of symptoms or syndrome, cause by HIV. AIDS stands for ‘Acquired Immune Deficiency
Syndrome’ and HIV ‘Human Immune Deficiency Virus’. This disease damages the immune system has great
extent and makes the body prone to infections and diseases. The susceptibility of the body to diseases increases
if the syndrome progresses. AIDS is also referred to as advance HIV infection or late stage of HIV. People with
HIV may develop AIDS if not diagnosed until late or don’t consistently take their antiretroviral therapy. The
AIDS virus and AIDS symbiotic pathogens immunity suppressing moieties in humans is demolished by the use
of the diamagnetic semiconducting molecular crystal tetra silver tetroxide Ag4O4. A single intravenous injection
is required for the efficiency of the level 40 ppm of the human blood. The device accommodates 2 mono silver
ions and 2 trivalent silver ions which is competent of firing and electrocuting the AIDS virus, pathogens and
other ISM into the blood stream the electron triggered by a pathogen. When a proliferating virus and ISM fired
continuously in a redox chelation mechanism then the resulting became a divalent silver moiety which binds to
the active sites and destroy all of them. These devices are through innocuous and environmentally safe but yet, it
may apply stress in liver which causes hepatomegaly, but keeps the liver function unaffected.
KEYWORDS: AIDS, silver tetroxide, Molecualr crystal devices.
INTRODUCTION:
The Human Immune Deficiency Virus, well know as
‘HIV’ is a very fatal virus which destroys and damages
the immune system of our body. The immune system of
our body is the shield that keeps various diseases and
infections at bay. Unattended HIV damages the CD4
cells-a type of immune cells called T cells1.
Hence, with the passage of time, body gets prone to
several infections and cancers due to a heavy destruction
in the CD4 cells. The HIV doesn’t spread in air, water or
casual contact. This virus can be spotted in all body
tissues. It can only be transmitted through the body
fluids of an infected person like blood, saliva and
semen2.
Received on 25.10.2018 Modified on 20.12.2018
Accepted on 19.01.2019 © RJPT All right reserved
Research J. Pharm. and Tech. 2019; 12(3): 1418-1424.
DOI: 10.5958/0974-360X.2019.00236.1
A perfect cure for the life long lasting HIV is still under
research. Although a perfect cure to the virus has not
been found, but the longevity of a patient’s life, affected
by HIV can be increased with a therapy called as
antiretroviral therapy, HIV can be managed with a lack
of any treatment HIV can lead to an even fatal diseases
called as AIDS. AIDS is a kind of diseases where in the
body of the victim turns too weak to fight against other
diseases and infections. AIDS is actually a syndrome
called by the HIV virus. An HIV affected person may
also develop AIDS develop AIDS if they have
antiretroviral treatment resistant HIV3.
If AIDS once develops, it simply indicates the fact that
the immune system of the patient’s body is severely
compromised and weakened. It shows that the immune
system has been weakened to the point where it can no
more fight against the diseases and infections. This
makes the patient prone to a several number of diseases
and illness, AIDS shows way to a large number of
illnesses, including pneumonia, tuberculosis, oral thrush,
CMV cryptococcal meningitis, toxoplasmosis and even

Research J. Pharm. and Tech. 12(3): March 2019
1419
cancer4, 5.
Over 25 antiretroviral therapy medications are approved
to treat HIV they function to prevent HIV from
destroying CD4 cells. They reduce the risk of developing
complications as well as virus transmission to others.
These antiretroviral medications are grouped into 6
groups6
• Nucleoside reverse transcriptase inhibitors (NRTI)
• Non-nucleoside reverse transcriptase inhibitors
(NNRTI)
• Protease inhibitors
• Fusion inhibitors
• CCR5 antagonists, also called entry inhibitions
• Integrase strand transfer inhibitor.
Figure 1: Frame work of the innovation
This invention of molecular crystal is also known as
anti-AIDS device. This device contains a crystal of
semiconductor tetra silver tetroxide (ag4o4) which carries
2 monovalent silver ions and 2 trivalent silver ions per
molecule1. It has definite structural configurations which
helps to binds in killing the viruses by binding with them
and thus form silver entity. So that’s why a single
intravenous injection destroys the AIDS virus in human
(2).It also said that this device is capable of killing
pathogens and cleaning the blood stream of ISM and
also said that it restores the immune system3.
The present piece of innovation is conceptualized based
on the prior explanation in applicant U.S. patent No.
5336499.4It revealed that bacteria, algae and the AIDS
virus can be destructed and inhibited in the nutrient life
supporting system by using the silver oxide device.5 It
has been revealed that 18 ppm above stated crystal
devices have a capability to terminate the AIDS virus
completely successive to the filing of the foregoing
patent, additional testing threw light on the fact that
complete a 100% of the AIDS virus could be destructed
in invitro at 20 ppm. Adding to the fact, the device has
been found to be complete safe device. It was found out
harmless when ingested and inhaled. It is non-poisonous
in nature.6
It has been encouraged by the evolution and the success
of the applicant which get permission to evaluate the
crystal in invitro against the murine acquired immune
deficiency syndrome (MAIDS). These evolutions are
only got licensed by the state of Israel, which was a
hospital namely as Kaplan hospital in Rehovot Israel.
And it is co-linked by the Hebrew University medical
school. Both of them jointly do the evolution work and
modify the evolution and improve the (MAIDS).7
The commencing assessment demanded experimentation
with several silver moieties specified in the above stated
patent, concentration, non-reactive buffers and modes of
administration. After a time, gap of approximately 18
month of prudent endeavour and preliminary let downs
victory was eventually attained in demolishing the
MAIDS virus in (C57BL) mice with a single intravenous
injection 7. The consequence of this test program
contained examples of U.S pat no. 5336499 after
attaining success with mice the inventor experimented
the efficiency of the mentioned device on two selected
etiological groups of terminal AIDS patients in a clinic
in Tegucigalpa, Honduras, Central America.8
The AIDS patents consist of subgroups knowns as
etiological groups CANDIDIASIS and WASTING
syndrome are the current indicator of the diseases which
are the diagnosing for AIDS. Which have been expanded
by CDC (Centre for Disease Control and Preventation)
10. It is a disease control agency which control and
prevent the disease-causing pathogens the CDC giving a
major five category of diagnosing agent with an
approximate value and percentage for the distribution of
the electron among the AIDS patients. The treatment of
both the group of curing the candidates and the wasting
syndrome AIDS patients was treated by the tetrasil and
these two groups are approximately carrying one third of
the AIDS causes in the inventio.In Stedman’s medical
Dictionary the WASTING syndrome defines as a
condition of losing about 10% of total body weight and it
is cause by diarrhoea or fever which is associated with
AIDS.11
There are several objectives of this invention. But, the
sole aim of this invention is to provide for a molecule
scale device of a single tetra silver tetroxide crystalline
molecule. This can be marked as a gigantic stride in the
in the field of medication and biotechnology studies. It
can be proved as life saver as it has a dynamic ability of
rehabilitating the exemption of AIDS afflicted in human
beings. Its capability can be imagined from the fact that
it can cure the AIDS afflicted in human beings from the
two AIDS etiological sub categories, the disease named
CANDIDAISES and even the WASTING syndrome.12

Research J. Pharm. and Tech. 12(3): March 2019
1420
The above-mentioned objective is the main objective.
Not the only one the invention is so dynamic in its nature
that it has a wide scope of objective. In the earlier arena
several injection and treatment were being provided for
AIDS affliction. But, now by the help of this invention
immunity can be gained back in the above-mentioned
AIDS afflicted human beings. In the case of AIDS
treatment has been further simplified in this invention.
Application of just a single injection is so powerful and
efficient that it can single dosely help in restoring the
immunity of person affected by AIDS.13
Adding to the above-mentioned objective, this novel
invention is sufficiently efficient to the end of the
existence of immune suppressing moieties (ISM) in
human. It is to be noted that ISM in human demonstrates
AIDS disease of the above stated AIDS etiological
subgroups. It does not regard to the fact whether the ISM
was HIV induced or not it is previously known that even
human can manifest AIDS and yet remain HIV negative.
This invention can hence help in restoring immune
system in the human which is mentioned above. This
adds silver to the invention14. Adding a further star to the
objective list of this invention, there is another important
objective of this invention is AIDS afflicted humans
have the AIDS virus in their system. This new invention
is able to destroy even those AIDS virus in the system of
the above- mentioned AIDS afflicted humans.
ENCAPSULATION:
Figure 2: Encapsulation
This invention shows correlation with a molecular scale
device. It is efficient in destroying the AIDS virus.
Additionally, it can also cleanse the bloodstream of
human beings and make it free from pathogens. It can
also help in returning back immunity to AIDS patient by
curing diseases like candidiasis and wasting syndrome
categories. The above-mentioned molecular device
includes a single crystal of tetra silver tetroxide15. The
crystal lattice of this molecule displays a unique
structure. This uniqueness in the crystal lattice structure
is because it is a diamagnetic semiconducting crystal
consisting of two mono and two trivalent silver ions
which in effect are capable of “firing” electron under
certain conditions it will end the existence of AIDS virus
and other pathogens and immune suppressing moieties
(ISM).16 This occurs not merely thorough the electro
cation mode, but also by a binding and chelation of
divalent silver. The terminating outcome of the electron
transfer redox that happens when the monovalent silver
ions are oxidised and the trivalent ions are reduced in the
crystal.17
The trivalent ions are reduced within the crystal. The
active sites of the AIDS virus, pathogens and ISM act as
the main point where the binding or the chelation effect
occurs. Owing to the exceeding minuscule size of a
single molecule of this crystal and many millions of this
device may be used up in concert to destruct a virus
colony to cleanse life support system. Hence an optimal
of 40 ppm of the device by weight of human blood was
found to be coefficient to completely exterminate AIDS.
The optimal concentration mentioned or recommended
in applicant. The AIDS virus in vitro is even less than
half of the above -mentioned concentration.18,19
The original destruction of pathogens, ISM and the
AIDS virus is accomplished by injecting of the device.
The injection is done with distilled water that is done
with a non- reacting electrolyte directly. The human
injected in the manner were inspected after three weeks
or more. On being composed with similar human that
had been given placebos. They were found to have been
completed cured AIDS. Moreover 3 out of 4 WASTING
syndrome terminal patients were yet alive after a year
and a half had clasped from their initial time.18
The present invention can view in the light of the
accompanying example. It would help in making other
object and feature of the present invention become more
vivid and transparent. It should acknowledge that the
escorting example illustrate favoured manifestation of
the present invention. They are not intended as a method
or means of defining the limitation and scope of the
present invention.17
ARGUMENTATION:
Figure 3: Argumentation

Research J. Pharm. and Tech. 12(3): March 2019
1421
This invention shows relation with the improvisation in a
treatment for AIDS including the use of electron, active
molecular crystals of tetra silver tetroxide. The
extemporization assimilates curing of non-terminal
AIDS patients with 15ppm of tetroxide along with the
regulation of slow injections to terminal patients at
40ppm. It is to be done so that the side effects can be
reduced like benign hepatomega.22.
It was believed that 40 ppm concentration might be too
high for non-terminal and the new AIDS cases as a result
arranged for clinical studies by a contract research
organisation named EXETEC LAB in HONDURAS on
terminal AIDS patient was made slow infusion 4 at 15
ppm of tetroxide was used. All AIDS patients were cured
and none showed hepatomegaly. Then arrangement for
toxicity test in rats were made to study the parameter of
intravenous injection. The test was carried out by
HARLON BIOTECH ISRAEL on Sprague -dawley rats.
The conclusion was reported on 10th may, 2001 which
showed that with respect tetrasil concentration of
48mg/kg in correspondence to 800 ppm in blood
administered by slow 4 infusion and corresponding to
about 20x the expected applied curative extent 40ppm in
blood may be regarded as at least artic dose level not
showing an acute toxic rise.23,13. With this particular
further action were taken for slow infusion clinical
studies with patients in advance or terminal stages of
AIDS in the republic of SA. The test was done of 8
elephants showing WASTING syndrome or carinii
pneumonia aetiologies of AIDS. They were tested with
tetrasil at 40 ppm, in slow 4 injections. Except for 3
hepatomegaly affected patients, all were cured of AIDS.
The sole motive of this invention is to decrease the
collateral side effects to patients afflicted with AIDS.25,26
AIDS undergoing tetrasil therapy it especially decreases
the side effect of hepatomegaly. Another objective of
this invention is to quantify the tetrasil 4 treatment of
non- terminal AIDS patients.it will noted that 8 out of 10
patients treated suffered from hepatomegaly 4 patients
accomplished fatigue and 1 suffered from pain
(headache)27. This invention is solely concerned with
extend of a minimum side effect therapeutic doses of
tetrasil for non-terminal patients. In essence, this
invention scrutinizes itself with improvisations in tetrasil
therapy of AIDS patients.28
Without any comprise in efficacy detailed description of
specific examples improvements in tetrasil AIDS therapy
were experimented clinically with variable of tetrasil
dosage concentration type of patient and length of time
administration of tetrasil to meliorate side effects with
other object and features of the present invention shall
become more transparent to those skilled in the art when
considered in view of the accompany examples the
assisting examples illustrate preferred embodiments of
the present invention. It should be admitted that those
experienced in the skill frame an oral administered tablet
of tetra oxide amended in a managed release vehicle
such as entering coating for delivery to the blood stream
establishment on the favoured embodiments of the
present invention.29
SKIN CANDIDAISISHEALED BY THE CRYSTAL
DEVICE:
Figure 4: Skin candidaisishealed by the crystal device
The invention establishes relation with the use of
electron active molecules crystal of tetra silver tetroxide
(Ag4O4) for the treatment and cured of dermatological
skin diseases like ranging from dermatitis, acne and
psoriasis to herpes and skin ulcers. The reference which
mentioned before reveals that tetra silver tetroxide
devices kills or hinder a wide variety of pathogens
ranging from gram positive and negative bacteria (e.g. E.
coli and staphylococcus aureus) algae and mold (e.g.
chlorella and candida albicans) and the AIDS virus said
reference include the explanation of mechanism through
which said molecular crystal device work. The
succeeding result and concept of the instant inventor
were presented at a seminar called “Incurable Diseases
Update” (Weizmann Institute of Science, Rehovot, Israel
Feb 11, 1998). The presentation was titled as beyond
antibiotics non- toxic disinfectants and tetrasil made
mark of applicant for the tetroxide. 30
In the article mentioned before, it was shown that the
impact of the electron transfer involved in concern with
the tetroxide, remarkable gave it even more powerful
germicide that other silver entities. The instant inventor
holds patent for multivalent silver antimicrobial for AG
2 and for AG 3and while these entities are stronger
antimicrobial than AG 1 compound they pale by
comparison to the tetroxide and so does colloidal silver
which get its germicidal properties from trace silver ions
that it generates in various environment. Accordingly,
the oligodynamic properties of these entities may be
summarized as such which is referred to as the Horsfall
series.

Research J. Pharm. and Tech. 12(3): March 2019
1422
Ag4O4>Ag (3)>Ag (1)>>>>Ag (1)(33):
There was another distinctive property of the tetroxide. It
did not stain organic matter like skin unlike Ag (1)
compound additionally it was stable.The main objective
of this invention is to use tetra silver tetroxide molecules
devices to cure dermatological disorders.31
Another objective of this invention is to control
incurable dermatological diseases by the use of tetra
silver tetroxide molecule devices. Still another objective
of this invention is to reduce the time of affliction of
dermatological condition of diseases by usage of tetra
silver tetroxide molecule. One more objective of this
invention is utilization of said device in the above-
mentioned dermatological application without skin
staining.32
SYNOPSIS:
Figure 5: Synopsis [ Terrsail-therapeutic skincare ointment]
This invention can be related to a molecular scale device,
which consisting a single crystal of tetra silver tetroxide.
Several trillion of these molecules can be used in many
pharmaceutical formulations and therapies to induce the
treatment and cure of several dermatological diseases.
These dermatological disorders may vary and include
ECZEMA, PSORIASIS, DERMATITS diseases
including SKIN ULCER, undefined tropical diseases,
shingles, rashes, bedsores, cold sores, blisters, boils,
herps simplex, acne, pimple, skin chafing, cracking,
itching, skin peeling, and warts.33
In particular the invention shows relation to method for
treating dermatological skin disease which comprises of
applying a composition of tetra silver tetroxide directly
to affected skin areas, said composition has to be free of
added oxidising agent. The crystal lattice of the (Ag4O4)
molecular device works against pathogens. It operates by
transferring electrons from its two monovalent silver
ions to the two trivalent silver ions in the crystal
contributing to the death of pathogen traversing their
cells membrane surface. This electrocutes the pathogens
the electrons are driven out of their balanced crystals by
labile groups like NH, NH2, s-s and SH comprising
pathogens cell membrane surface. Normal cells would
remain unaffected as they do not proliferate fast enough
to expose these labile bonds.34
The kA of AgO4 is 7.9*10-13, So, the molecule will
remain undisturbed unless more stable complexes are
formed with ligands as those compressing the pathogens
cells membrane surface in a dynamic state. The electron
transfer, which is a redox reacting result in a monovalent
Ag ion getting oxidised to Ag 2 and trivalent Ag ions
getting reduced to the same end product. the affinity of
monovalent silver for certain elements like sulphur and
nitrogen is quite exceeded here because divalent silver
will not only bind to those elements like silver but will
also form chelate compound with their ligands. The
powerful covalent bonding forces drives the molecular
crystal attraction for cell. Rigorous experimentation
shows that silver tetroxide was comparatively non-toxic.
Commercial concentrate was formulated with 2% of the
tetroxide as said oxide was effective at ppm
concentration to kill pathogens. an EPA registration
number was obtained for accepted of said oxide in
commerce. 3% concentrate of the oxide was used for a
necessary series of toxicity test. It was evaluated by a
certified laboratory employing good laboratory practice
according to the code of federal regulation.35
Ensuring evaluation showed that until the person was
more to silver allergies, the pure tetroxide could be
applied to the skin without any ill effect or evidence of
irritation inspect of the fact that said oxides a powerful
oxidising agent. In earlier patents related to various uses
of oxides it was postulated that oxide needed to be cured
in combination with an excess of strong oxidising agent
like persulfate so to kill pathogens. But the presence of
additional oxide is unnecessary and undesirable for
treatment of skin disease mentioned herein. The mode of
application of the oxide of the invention as a topical agent
is preferable. It can be used either as a powder or in non-
sprayable or sprayable form. Non -sprayable forms can be
semi solid forms consisting a carrier indigenous to tropical
application and having a dynamic viscosity preferably
greater than the water. But they are not restricted to
suspension, emulsion, cream ointments, powder liniments
salves and other such items. They may be mixed or
sterilized agents such as thixotropies, stabilizer, wetting
agent etc. the advantageous vehicle for non-spray able
topical preparation incorporates ointment bases, e.g.,
polyethylene glycol-1000, preferable ophthalmic vehicle,
cream and gets as well as petroleum jelly. when the oxide
is applied to the skin in combination with a carrier like
one or more of the carrier at a level of from about 28 to
250, 000ppm or more than 400 to 50, 000ppm based on
the weight of the carrier and applied to the skin 1 to 3
times per day until the condition is cured or satisfactory
controlled mostly the composition dosage level from
about 10 to 500 mg per cm of the skin surface. It can be
used in many skin dieses and condition expects nail fungi.
After a lot of experiment, it was found that petroleum jelly
is best for commercial product.36, 37

Research J. Pharm. and Tech. 12(3): March 2019
1423
Animal and mammalian skin, especially human skin is
multifunctional functional organ. The skin provision
external covering to protect the body performs many
specialised functions like breathing, perspiring and oil
production. Oil production is necessary for skin as a
protection. It works when sebum, an oily substance is
release from the sebaceous glans. This allows the skin to
protect itself from the environment by moisturizing and
making itself waterproof. The skin is the most
environmentally stressed organ in mammals specially
humans. The skin gets exposed to toxic chemicals and
hostile environment. It is the only organ which is directly
exposed to UV light in the presence of the oxygen. High
exposure to the skin to UV light damages skin resulting
in sunburn, photoaging, carcinogenesis and other related
skin disorders.38
Particularly, human skin is a composite material of the
dermis stratum coecum is the top most layer of
epidermis. It’s the skin stiffest layer and the most
affected by surrounding environment. Below epidermis,
papillary dermis is the topmost layer of the dermis. It is
made up of relatively loose connective tissue that defines
the microrelief of the skin below papillary dermis there
is reticular dermis which is tight connective tissue which
is partially organised. Reticular dermis is also related
with coarse wrinkles subcutaneous layer at the bottom of
the dermis layer. Protection, excretion, secretion,
absorption thermoregulation, pigment agenesis,
accumulation sensory perception and regulation of
immunological process are the main function of skin
which are harmfully affected by structural changes in
skin due to the aging and high sun exposure skin aging
damages barrier function and decreased turnover of the
epidermal cells. 39
Figure 6: Diagrammatic representation of AIDS Virus (HIV)
Density and geometry of the network of collagen and
elastic fibre tissue control the mechanical property of the
skin skins wrinkling and skin surface roughness are due
to damaged collagen. Vitamin D reduces due to the skin
aging. Exposure to UV light in presence of oxygen
creates free radicals which lead to many skin disorders
diseases or condition. These free radicals frequently
activate release of inflammatory mediator visible as sun
burn cytoskeletal alterations breaking down collagen in
skin and may lead structural change in DNA. Tropical
pharmaceutical application shield skin from sun harmful
effect sunscreen which protects the skin which include
photo-protectant material like titanium and zinc oxide.
Many vitamins and minerals have been individually
administered to treat certain skin and other problems due
to the deficiency of the vitamins and minerals. Vitamin
A helps acne treatment and wound healing. Vitamin C
prevents skin bruises and helps wound healing. Vitamin
E is an antioxidant and copper help in treatment of
elastic tissue defect. Topical use of vitamin C wards off
sun damage reduces breakdown of connective tissue and
improves collagen synthesis. Topical use of vitamin E
acts as anti-inflammatory agent for skin moist ration for
UV protection of cells. Tetroxide did not stain organic
matter unlike Ag (1) compound. It is additionally light
stable.40, 41, 42
The skin disease is caused by one or more autoimmune
disorder rather than by pathogens. a circulatory condition
or a neurological condition or else it includes at least one
of the eczemas, psoriasis, dermatitis, ulcers, shingles,
rashes, bed shores, cold sores, blisters, boils, herps, acne,
pimple, skin chafing, skin cracking, skin itch, skin
peeling, heat rashes, leprosy, dermal tuberculosis, and
warts. Pharmaceutically acceptable salts preferable do
not include contain salts. They help in breaking down of
the oxide lattice present in the metal oxide composition
of the invention.42, 43, 44
CONCLUSION:
Grounded on all the text data described above, the curing
technique analogous with the use of tetra silver tetroxide
to manage and cure at least some skin diseases seem to
be more than just mere destruction of pathogens and
ameliorating infections which tend to aggravate disease
and decelerate the natural healing process. This
invention can be manifested in many forms without
removing the spirit or necessary characteristics the
present manifestations are therefore illustrative and not
restrictive.
ACKNOWLEDGMENT:
The authors thank Vels Institute of Science, Technology,
and Advanced Studies management for rendering
constant support in writing the review article
successfully.
The authors do not have any conflict of interests and
both the authors have contributed equally for bringing
this review article effectively.

Research J. Pharm. and Tech. 12(3): March 2019
1424
REFERENCE:
1. www.medicalnewstoday.com
2. www.avert.org>about- hiv-aids
3. www.healthline.com
4. www.emedicinehealth.com
5. www.wikipedia.org
6. Medlineplus.gov>HIV aids
7. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Method of curing AIDS with tetrasilver tetroxide molecular crystal
devices. United States patent US 5, 676, 977. 1997 Oct 14.
8. Antelman MS, inventor; Jonas N and Co Inc, assignee. Divalent
silver alkaline bactericide compositions. United States patent US
5, 073, 382. 1991 Dec 17.
9. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Molecular crystal device for pharmaceuticals. United States patent
US 5, 336, 499. 1994 Aug 9.
10. Antelman M, inventor; Marantech Holding LLC, assignee.
Compositions using tetrasilver tetroxide and methods for
management of skin conditions using same. United States patent
application US 10/630, 737. 2004 Feb 5.
11. Antelman MS. Multivalent Silver Bactericides. InPRECIOUS
METALS-CONFERENCE- 1992 (Vol. 16, pp. 151-151).
PERGAMON PRESS.
12. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Molecular crystal device for pharmaceuticals. United States patent
US 5, 336, 499. 1994 Aug 9.
13. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Molecular crystal redox device for pharmaceuticals. United States
patent US 5, 571, 520. 1996 Nov 5.
14. Fox Jr CL, Modak SM, inventors; Columbia University of New
York, assignee. Method of inhibiting the transmission of AIDS
virus. United States patent US 4, 952, 411. 1990 Aug 28.
15. De Cuellar BR, Bello LA, inventors; Laboratorios Biochemie de
Mexico, assignee. Method of manufacturing a composition for
treating skin lesions. United States patent US 4, 828, 832. 1989
May 9.
16. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Molecular crystal device for pharmaceuticals. United States patent
US 5, 336, 499. 1994 Aug 9.
17. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Method of curing AIDS with tetrasilver tetroxide molecular crystal
devices. United States patent US 5, 676, 977. 1997 Oct 14.
18. Antelman MS. Anti-pathogenic multivalent silver molecular
semiconductors. In PRECIOUS METALS-CONFERENCE- 1992
(Vol. 16, pp. 141-141). PERGAMON PRESS.
19. Antelman MS, inventor; Marantech Holding LLC, assignee.
Compositions for facilitating skin growth and methods and articles
using same. United States patent US 6, 669, 966. 2003 Dec 30.
20. Duesberg PH, Ellison BJ. Is The AIDS Virus A Science Fiction?
Immunosuppressive Behavior, Not HIV, May Be the Cause of
AIDS. Policy Review. 1990; 53:40-51.
21. Improvements in curing AIDS with tetra silver tetroxide molecular
crystal devices. WO2003043537A1-2003-05-30 - 5334588 August
2, 1994 - Fox, jr.
22. Antelman MS, inventor; Antelman Technologies Ltd, assignee.
Method of curing AIDS with tetrasilver tetroxide molecular crystal
devices. United States patent US 5, 676, 977. 1997 Oct 14.
23. Method of curing AIDS with tetra silver tetroxide molecular
crystal device.
24. US08658955 -1996-05-31 5089275 February 18, 1992 –Antelman
25. Antelman MS, inventor; Jonas N and Co Inc, assignee. Trivalent
silver water treatment compositions. United States patent US 5,
223, 149. 1993 Jun 29.
26. Antelman MS, inventor; Jonas N and Co Inc, assignee. Divalent
silver bactericide for water treatment. United States patent US 5,
017, 295. 1991 May 21.
27. Antelman MS. Divalent silver oxide bactericides. Patent Number.
1992 Feb.
28. Antelman MS, inventor; Jonas N and Co Inc, assignee. Divalent
silver bactericide for water treatment. United States patent US 5,
017, 295. 1991 May 21.
29. US09552172 -2000-04-18 -tetra silver tetroxide treatment for skin
conditions
30. JP2001549670A -2000-10-20-compositions and methods for the
promotion and skin conditions the treatment of skin proliferation.
31. PCT/US2000/029115 – 2000-10-20- compositions and methods
for facilitating skin growth and managing skin conditions.
32. Antelman MS, inventor; Marantech Holding LLC, assignee.
Tetrasilver tetroxide treatment for skin conditions. United States
patent US 6, 258, 385. 2001 Jul 10.
33. US10630737–2003-07-31- Compositions using tetra silver
tetroxide and methods for management of skin conditions using
same.
34. US11318648 –2005-12-27- Compositions using tetra silver
tetroxide and methods for management of skin conditions using
same.
35. Antelman MS, inventor; Marantech Holding LLC, assignee.
Tetrasilver tetroxide treatment for skin conditions. United States
patent US 6, 258, 385. 2001 Jul 10.
36. US4828832A-1989-05-09 –Methods of manufacturing a
composition for treating skin lesions.
37. US6669966B1-2003-12-30-Composition for facilitating skin
growth and methods and article
38. US20040022868A1-2004-02-05-Composition using tetra silver
tetroxide and methods for management of skin condition.
39. www.medicalnewstoday.com
40. www.avert.org>about- HIV-aids
41. www.healthline.com
42. www.emedicinehealth.com
43. www.wikipedia.org
44. Medlineplus.gov>HIV aids